Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
Titel:
Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
Auteur:
Puvvada, Soham D. Guillen-Rodriguez, José Kumar, Abhijeet Inclán, Lora Heard, Kara Rivera, Xavier I. Anwer, Faiz Schatz, Jonathan H. Mahadevan, Daruka Persky, Daniel O.